

Epidemiological surveillance of pancreatic cancer in the North region of the state of Rio Grande do Sul

Vigilância epidemiológica do câncer de pâncreas na região Norte do estado do Rio Grande do Sul

Henrique Mezzomo Pasqual¹ , Luciano Luiz Alt¹, Clarissa Possamai Tres¹, Monica Mânica¹, Vitoria dos Santos Magalhães¹, Paulo Roberto Reichert¹, Victor Campos Horbach¹, Thais Dall'Acqua Jost¹, William Patrick Menegussi¹, Bernardo Luiz Lazarotto de Lani¹, Anna Lourdes Gueller Becker¹, Henrique Cassel de Oliveira¹

ABSTRACT

Introduction: Pancreatic neoplasia is considered a serious disease, associated with high mortality rates and late diagnosis. This pathology corresponds in the Brazilian scenario, about 2% of the diagnosed cancers. The main risk factors are: advanced age, male sex, black race, smoking, obesity, diabetes, pancreatitis, excessive alcohol use, as well as genetic syndromes such as non-polypoid hereditary colorectal cancer (HNPCC) and breast and ovary (associated with BRCA2 mutations). **Objectives:** The objective of this study was to identify the main risk factors and to verify which variables related to diagnosis, treatment and staging were present in cases of pancreatic cancer registered in the São Vicente de Paulo Hospital (HSVP) epidemiological surveillance system for cancer. **Methods:** A cross-sectional, predominantly descriptive, retrospective study using data from patients with pancreatic cancer at the Hospital São Vicente de Paulo (HSVP) was conducted between 2007 and 2017. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 18.0, (SPSS Inc., Chicago, IL, USA). **Results:** A higher incidence was observed in men (51.2%), the predominant age range was between 66 and 80 years (41.9%), the white color was prevalent (91.7%), (13,3%) were users of alcoholic beverages, (33.9%) were smokers or former smokers, (44.9%) were in stage IV when diagnosed and the predominant life span was between 1 and 10 months (35.7%). **Conclusions:** The risk factors recommended by the literature, with the exception of the black race, are present in the epidemiological profile traced by the present study. In addition, high mortality and late diagnosis were also evidenced through the stage during the diagnosis and the low survival rate. Thus, the study is relevant for the adoption of future preventive and diagnostic measures.

Keywords: Pancreatic neoplasms; Epidemiology, Descriptive; Risk factors; Outcome and process assessment (health care).

1. Universidade de Passo Fundo, Department of Medicine - Passo Fundo - Rio Grande do Sul - Brazil.

Financial support: none to declare.

Conflicts of interest: The authors declare no conflict of interest relevant to this manuscript.

Correspondence author: Henrique Mezzomo Pasqual.

E-mail: henriquemezzomo@icloud.com

Received on: July 16, 2019 | **Accepted on:** March 25, 2020 | **Published on:** June 10, 2020

DOI: <https://doi.org/10.5935/2526-8732.20200009>



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>).

RESUMO

Introdução: A neoplasia pancreática é considerada uma doença grave, associada a altas taxas de mortalidade e diagnóstico tardio. Essa patologia corresponde, no cenário brasileiro, a cerca de 2% dos cânceres diagnosticados. Os principais fatores de risco são: idade avançada, sexo masculino, raça negra, tabagismo, obesidade, diabetes, pancreatite, uso excessivo de álcool, bem como síndromes genéticas, como câncer colorretal hereditário não polipoide (HNPCC) e de mama e ovário (associados a mutações no BRCA2). **Objetivos:** O objetivo deste estudo foi identificar os principais fatores de risco e verificar quais variáveis relacionadas ao diagnóstico, tratamento e estadiamento estavam presentes nos casos de câncer de pâncreas registrados no sistema de vigilância epidemiológica do Hospital São Vicente de Paulo (HSVP). **Métodos:** Foi realizado um estudo retrospectivo transversal, predominantemente descritivo, com dados de pacientes com câncer de pâncreas do Hospital São Vicente de Paulo (HSVP) entre 2007 e 2017. A análise estatística foi realizada usando o Statistical Package for the Social Sciences (SPSS), versão 18.0, (SPSS Inc., Chicago, IL, EUA). **Resultados:** Observou-se maior incidência nos homens (51,2%), faixa etária predominante entre 66 e 80 anos (41,9%), predominância da cor branca (91,7%), (13,3%) usuários de bebidas alcoólicas, (33,9%) eram fumantes ou ex-fumantes, (44,9%) estavam no estágio IV quando diagnosticados e a expectativa de vida predominante foi entre 1 e 10 meses (35,7%). **Conclusões:** Os fatores de risco recomendados pela literatura, com exceção da raça negra, estão presentes no perfil epidemiológico traçado pelo presente estudo. Além disso, a alta mortalidade e diagnóstico tardio também foram evidenciados através do estágio durante o diagnóstico e a baixa taxa de sobrevida. Portanto, o estudo é relevante para a adoção de futuras medidas preventivas e de diagnóstico.

Descritores: Neoplasias pancreáticas; Epidemiologia descritiva; Fatores de risco; Avaliação de resultados e processos (cuidados de saúde).

INTRODUCTION

Pancreatic cancer is responsible for about 2% of all cancers diagnosed and 4% of all deaths in Brazil due to this pathology. Among all subtypes of pancreatic tumors, the most prevalent is adenocarcinoma (originating in glandular tissue), corresponding to 90% of the cases diagnosed.^[1]

As a result of its difficult early detection, associated with the aggressive behavior of such a tumor, pancreatic cancer presents a significant mortality rate, with a five-year survival rate of about 2% to 9%,^[2] being considered a lethal condition of reserved prognosis and increasing incidence - predicted to be the second leading cause of death caused by cancer in some regions by 2030.^[3] In the United States, as in other developed countries, this pathology currently ranks fourth among the causes of death by cancer.^[4]

The main risk factors identified for pancreatic cancer are, in addition to advanced age, male sex, afro-descendant ethnicity, smoking, obesity, long-standing diabetes, pancreatitis and excessive alcohol use. Also, several genetic syndromes are associated with an increased risk of developing pancreatic neoplasia, such as hereditary pancreatitis, hereditary non-polypoid colorectal cancer (HNPCC), hereditary breast and ovary cancer (associated

with BRCA2 mutations), familial atypical multiple melanoma syndrome, Peutz-Jeghers syndrome, ataxia-telangiectasia and von Hippel-Lindau syndrome.^[4,3,5] Thus, a better understanding of the risk factors and clinical symptoms associated with this disease are fundamental to support possible preventive measures and/or early detection, both aiming benefits towards health professionals and general population.^[2]

Considering the prevalence and aggressiveness of this disease, the present study intends to evaluate the epidemiology of pancreatic cancer in a tertiary hospital in the northwest of Rio Grande do Sul, Brazil. It is expected that with the analysis of these data mechanisms of intervention may be created, aiming both prevention and early diagnosis of this pathology, enabling patients to be properly identified and treated when affected.

OBJECTIVES

This article aims to analyze the evolution of the analytical and non-analytical cases of pancreatic cancer registered in epidemiological surveillance of neoplasms system of a tertiary hospital in the northern state of Rio Grande do Sul, in a time frame of ten years. Also, it aims to describe the prevalence of pancreatic cancer in this decade, as well as to characterize the cases according to the

demoGraphic and clinical profile of the patients. Furthermore, verify which variables related to diagnosis, treatment and staging are associated with the cases, and identify the main risk factors associated with the reported cases.

METHODS

A retrospective cross-sectional, predominantly descriptive study was carried out using data provided by medical records and a hospital registry of patients identified as having pancreatic cancer at São Vicente de Paulo Hospital (HSVP), among the years of 2007 and 2017.

HSVP is located in the interior of the state of Rio Grande do Sul and is a highly complex tertiary hospital with more than 700 hospital beds. The municipality contains approximately 200,000 inhabitants and is a regional health reference for the states that make up the southern region of the country.

After ethic approval issued by both the Ethics Committee of the HSVP and the Ethics Committee of the University of Passo Fundo, registered as protocol number 3,095,106, information based on medical records and the hospital registry for pancreatic cancer was consulted, and later on, used to elaborate a database.

The inclusion criteria of the study were analytical cases of malignant pancreatic neoplasia (CID 10 - C25) included in the HSVP registers from January 2007 to December 2017. The analytical cases represented patients with malignant neoplasia, whose planning and treatment of the tumor followed the indication of hospital guidelines or were executed, as well as its follow-up, according to its guidelines. Therefore, those patients were considered appropriate for later on analysis of the quality of care provided by the hospital.

Cases excluded from the study included benign analytical cases, analytical cases that had a pending or incomplete diagnostic status, multiple records.

The variables analyzed by the study were sex, age, ethnicity, family history, history of smoking and alcohol consumption, previous diagnoses of neoplasia, diagnosis base, primary tumor location, initial clinical staging, TNM staging, metastasis location, first treatment performed in the hospital, staging at the end of the first treatment, presence of more than one tumor and time of survival.

Statistical analysis was performed using the statistical software *IBM Statistical Package for Social Sciences* (SPSS), version 18.0, (SPSS Inc, Chicago, IL, USA), in a descriptive and inferential manner for the study variables.

For qualitative variables, the chi-square test was applied and, for the quantitative, the T-student test. To verify the independence between the variables that were associated or not to the outcome, a non-parametric test with a significance level of 5% was used.

RESULTS

Among the 445 medical records analyzed, the results were categorized into the following variables: risk factors associated with the development of pancreatic neoplasia (gender, age, ethnicity, family history, smoking and alcoholism), evaluation at diagnosis (diagnosis, or previous treatments, presence of other primary tumors, TNM classification and initial staging of the disease), the treatment used (first hospital treatment) and the evolution of the pathology (localization of distant metastases), state of the patient after the first phase of treatment, survival time, deaths occurred).

Regarding associated risk factors, 228 patients were males (51.2% of the total sample), remaining 217 (48.8%) of the female sex. Mean age and ethnicity can be verified in Table 1 and in Graph 1.

Table 1. Age among patients.


Age	Total Of Patients	Percentage (%)
13	1	0,2
13 TO 45	19	4
46 TO 55	62	13,9
56 TO 65	130	29,2
66 TO 80	187	41,9
81 TO 96	47	10,5
96	1	0,2

Information regarding the existence of a family history of pancreatic neoplasia was present in only 202 of them (45.4% of the sample). Of those, only 63 (14.2%) had a positive family history, while 139 (31.2%) had a negative family history. As other risk factors, data concerning smoking and alcohol exposure can be seen in Graph 2.

The main sites of tumor location in the pancreas can be seen in Graph 3, predominantly in the pancreatic head.


Regarding the methodology used for the diagnosis, 238, that is, 53.5% of the patients had their diagnosis through histology of the primary tumor; 109 (24.5%) through histology of metastasis; and 88 (19.8%) employing image examination. The other diagnostic methods (tumor markers, cytology, clinical research and clinical diagnosis) obtained, together, 2.2%. However, of the 445 patient charts analyzed, 337 patients (75.7%) had no previous diagnosis and did not have any treatment, and a sample of 89 patients (20.0%) were already diagnosed, but without previous treatment. Only 19 patients (4.3%) had a previous diagnosis and treatment.

Regarding the occurrence of more than one primary tumor, 405 (91%) had no more than one tumor and 40 (9%) had another associated tumor.



Graph 1. Ethnicity.


*The prevalent ethnicity in the study was caucasian.



*Most patients did not consume neither alcohol nor tobacco.

Graph 2. Alcohol and tobacco consumption.

*Most patients did not consume neither alcohol nor tobacco.



Graph 3. Location of pancreatic neoplasia.
*Pancreatic head was the most common site of the tumor.

Initial staging of the neoplasia can be verified at Table 2. The most prevalent stage at the time of diagnosis was stage IV, with 200 patients (44.9% of the total patients/65.8% of the patients with medical records), followed by stages III and IB with 46 (10.3%/15.1%) and 21 (4.7%/6.9%), respectively.

Table 2. Initial cancer staging.

Initial Cancer Staging	Number Of Cases	Total Percentage (%)
IA	11	2,5
IB	21	4,7
IIA	16	3,6
IIB	10	2,2
III	46	10,3
IV	200	44,9
No data	141	31,7
Total	445	100,0

Regarding the first hospital treatment used in such cases of pancreatic neoplasia, data can be observed in Table 3. Many patients proceeded with complementary treatment, which can be seen in Table 4.

Regarding the main sites of distant metastasis, 215 (48.3%) of the 445 patients were evaluated. The other 230 patients did not develop metastases or these were not shown in their medical records. According to our study, the organ most likely to receive pancreatic metastasis was the liver, corresponding to 134 (62.3%). Out of the 134 patients, 84 of these

Table 3. First hospital treatment.

First Hospital Treatment	Total Of Patients	Percentual (%)
Any one	82	18,4
Surgery alone	153	34,4
Surgery plus radiotherapy	1	0,2
Surgery plus radiotherapy plus chemotherapy	2	0,4
Surgery plus Chemotherapy	47	10,6
Surgery plus Chemotherapy and other treatments	5	1,1
Surgery and other treatments	13	2,9
Surgery back surgery and other treatments	2	0,4
Surgery plus Chemotherapy and other treatments	2	0,4

(39%) had metastasis located only in the liver. The other 50 patients had metastasis in at least one other site, the main ones being: peritoneum, with 32 cases (14.9%), and lungs with 11 cases (5.1%).

Excluding the liver, the other main sites of metastasis were the peritoneum, with 82 cases (38.1%), of which only 45 (20.9%) were found in the peritoneum alone; and the lungs, with 25 cases (11.6%). Only 10 (4.6%) were strictly located in the lungs. Other organs affected by pancreatic metastasis were: stomach, small intestine, colon, biliary tract, mediastinum, bones, skin, brain, adrenals and lymph nodes.

Table 4. Complementary treatments pursued by patients.

Complementary treatments	Total of patients	Percentual (%)
Surgery and then other treatments	1	0,2
Only radiotherapy	7	1,6
Radiotherapy and chemotherapy	2	0,4
Radiotherapy plus chemotherapy and other treatments	1	0,2
Only chemotherapy	49	11
Chemotherapy and radiotherapy	2	0,4
Surgery plus radiotherapy and other treatments	1	0,2
Chemotherapy and other treatments	14	3,1
Only hormone therapy	1	0,2
Hormone therapy and chemotherapy	1	0,2
Only alternative sources of treatment	50	11,2
Alternative sources of treatment and chemotherapy	6	1,3
Alternative sources of treatment plus chemotherapy and other treatments	2	0,4
Alternative sources of treatment plus other treatments and then chemotherapy	1	0,2


Regarding the number of affected sites, 156 (72.5%) patients had only one site of metastasis, 49 (22.8%) had 2 sites, 9 (4.2%) had 3 sites and 1 (0.5 %) patients had 4 sites affected.

After undergoing first treatment for pancreatic cancer, 43 (9.7%) were in complete remission, and 168 (37.8%) died. More results obtained after undergoing first treatment for pancreatic cancer can be observed in Graph 4. A reason that caused a reduction to the analytical sample was the fact that these categories did not apply to 83 (18.7%) medical records since the data were not adequate to be categorized.


Regarding overall survival time, among the 445 files analyzed, 45.50% of the patients had a survival shorter than 1 month, as verified in Graph 5. As of mortality rates of pancreatic cancer in the analyzed population, it was observed that 272 (61.1%) patients died and only 8 (1.8%) of them were alive. This information was ignored in 73 of them (16.4% of the sample).

DISCUSSION

The present study shows results that need to be discussed to better understand the factors that

**Graph 4.** Outcomes after first treatment.

*Most patients showed poor outcomes after first treatment.



Graph 5. Overall survival.
*Most patients died in a period shorter than a month.

permeate and influence the aggressive behavior and unfavorable prognosis that pancreatic cancer presents.

When a family history of pancreatic neoplasia is assessed, it is made by analyzing the involvement of two first-degree relatives. The study, however, considered as family history any pancreatic neoplasia that has occurred in a first-degree relative. Several literature^[2,6] suggest that there is an established relation of family history as a risk factor for pancreatic neoplasia, with genetic mutations being the main responsible for the familial manifestations of the pathology.

The research, unlike data proposed by previous studies,^[7,8,9] showed a small association (14.2%) between positive family history and the diagnosis of pancreatic cancer. This data may be a result of the large number of medical records that contained missing data regarding the family history of the patients analyzed (54.6%).

Advanced age is an important non-modifiable risk factor for pancreatic cancer. In Brazil, pancreatic cancer is a rare entity when diagnosed before the age of 30 years, and it is more common to be diagnosed after the age of 60 years. Globally, about 90% of pancreatic cancer cases are diagnosed after age 55, varying in some countries. In the United States, the disease is more prevalent at 60 years of age and, in India, it becomes more frequent after 50 years of age.^[2]

The prevalence of pancreatic cancer varies according to ethnicity. Previous epidemiological

data indicate that a higher percentage of this diagnosis occurs in African Americans, rather than in caucasian individuals (15.8 vs 12.0 per 100,000).^[2] Although reasons for the higher prevalence of pancreatic neoplasia in Afro-descendants have not yet been adequately clarified, it can be attributed, in part, to the fact that this population has higher rates or is more related to greater exposure to other risk factors, to mention: smoking, alcohol consumption, high body mass index and higher incidence of diabetes.^[11,2]

However, this statement is not the only that applies, since there is also evidence of genetic association and underlying environmental gene alterations to explain at least some of the observed differences in incidence and prevalence among ethical groups.^[2,12]

The present study, in contrast to the data proposed in previous studies,^[4,10,2] did not show a direct relationship between Afro-descendant ethnicity and pancreatic neoplasia, since it resulted in a greater and significant prevalence of pancreatic neoplasia in individuals of white color (91.7% of the sample), with brown and black colors only in the minority (6.7% and 1.3%, respectively). However, the small sample and the ethnicity of the region in which the research was conducted should be taken into account, since the majority of the population in southern Brazil belongs to the caucasian ethnic group. Therefore, the prevalence of pancreatic cancer could be mainly linked to this ethnicity due to epidemiological reasons.

Another non-modifiable risk factor is gender, with pancreatic cancer being more common in men than in

women.^[18] Usually, the gender ratio is 6:1 in developed countries and 1:1 in developing countries,^[19] that is, overall, the gender distribution is tempered, given the regional variations that tend to show in this trend.^[20] Thus, the average incidence in developed countries for men is 8.5 per 100,000 and for women, 5.6 per 100,000, as illustrated by the United States in which the prevalence rate for men is 8.7 and for women 6.5. In developing countries, the incidence has an average for men and women of 3.3 and 2.4 per 100,000, respectively.^[21] Countries in East Africa, such as Kenya, have an incidence of 3.3 per 100,000 in men and 3.1 per 100,000 in women.^[22]

In comparison, Brazil has the following incidence rates: 5.3 per 100.00 for men and 4.1 per 100,000 for women. Worldwide, the incidence for men is 5.5 per 100,000 and 4.0 per 100,000 for women. Hence, it is observed that the Brazilian incidence rates of pancreatic cancer follow a worldwide trend and are consistent with the country's demographic situation,^[22] which was also observed in our study.

Finally, there are studies that try to explain the numbers as mentioned earlier; however, it is suspected that the risks for pancreatic cancer are slightly increased in men due to environmental factors such as tobacco.^[21] Data present in another study refer 20 to 30% of the prevalence of pancreatic neoplasia to smoking,^[24] highlighting the impact of smoking on the development of this cancer. The use of this substance favors the onset of the disease in three to nine years before those who have never used it.^[25] Therefore, the cessation of tobacco can be seen as a preventive measure.^[26]

As for alcoholism, the information collected showed a low rate of heavy drinkers, and it can be inferred that there is no well established correlation between the development of the disease and alcoholism. This information is well provided by the International Agency for Research on Cancer, whose conclusion is that there is no evidence to state that the risk of consumption can lead to the appearance of a pancreatic neoplasm.^[26]

Currently, population screening for pancreatic cancer is not recommended in Brazil because there is no scientific evidence to prove benefit in tracking the disease. In populations with higher risk for the development of pancreatic cancer, as carriers of syndromes, it is possible to adopt screening strategies in investigative protocols. Besides, the vast majority of patients with pancreatic cancer only present signs and symptoms of the disease in more advanced stages, at which point they have their first diagnosis.^[1]

Because many are asymptomatic, and those with clinical symptoms usually present them as non-specific, early diagnosis is a challenging subject regarding pancreatic cancer. More specific symptoms include weight loss, jaundice, malabsorption, pain, dyspepsia and nausea.^[29,30] Among the imaging methods for diagnosis, CT is the most widely used

and best validated to initially evaluate the patient with suspected pancreatic cancer^[29,30,31] and has shown to be extremely relevant in the present study.

Nevertheless, magnetic resonance imaging (MRI) is reserved for cases in which CT is inconclusive, such as presentation of isodense tumors.^[30,31] The use of endoscopic ultrasound can also diagnose tumors, being indicated for lesions smaller than 2cm or when other methods fail to diagnose, and there is an important clinical suspicion.^[30,31]

When evaluating tumor markers, CA-19-9 is the most widely used and best validated marker for pancreatic cancer. However, it should be used with caution since it is nonspecific, and can be altered in other benign conditions.^[32] Consequently, its use is restricted to the evaluation of therapeutic response in surgeries, neoadjuvance, or even to track tumor recurrences.^[30]

In the present study, the methods that provided the greatest number of diagnoses among the charts were histology of primary tumor and metastasis, and imaging methods. Tumor marker, cytology, clinical, and clinical research scored only 2.2% of the diagnosis, being the least used for that purpose. The percentage of use of these diagnostic methods corroborate with rates described in previous studies.

Moreover, the study estimated that 9% of patients had more than one primary tumor. It is estimated that the frequency of more than one primary tumor ranges from 2 to 17%,^[41] without necessarily being related to the pancreatic neoplasm. This can be explained because many habits and substances that are risk factors for pancreatic cancer are also present as risk factors in different types of tumors. Also, genetic syndromes may imply on that percentage, since they are often associated with more than a single tumor.

The pancreas is an organ that is placed in the upper portion of the abdomen. It is anatomically divided into parts called head, body and tail^[16] and it contains one endocrine and one exocrine portion. Ductal adenocarcinoma of the pancreas, which accounts for 95% of pancreatic cancers, originates in the exocrine part.^[3]

Regarding the anatomical location of the primary tumor, approximately 60-70% are found in the head of the pancreas, the rest being found in the body and tail, respectively.^[2] According to the Ministry of Health in Brazil, most cases affect the right side of the organ, where anatomically the pancreatic head is found.^[1] In the present study, 261 cases (58.7%) were located in the head region of the pancreas, followed by the body and tail region, which corroborates the epidemiological data found in the literature.

The TNM system is a tool for the staging in different types of cancer. This staging tool determines that T is assigned for tumor, N for lymph nodes and M for metastasis. The literature focuses on tumor staging, which uses TNM to be constructed, and can range

from 80 to 85% of the tumors as locally advanced or metastatic^[28] (stage IIB, III and IV). In the present study, the percentage of such stages was 81.1%. Although this value was consistent with scientific literature, it remains a high percentage, which indicates that the diagnosis of this tumor occurs late, and reasons implicated on that high rate may include the lack of initial symptoms, delay in seeking care or delay in treatment.^[28,33]

Once a tumor is diagnosed, the patient's assessment begins by defining the stage the patient is in and planning their treatment. Because pancreatic tumors usually take time to manifest symptoms and are difficult to diagnose, the vast majority are only diagnosed in stages III or IV. That is, tumors with large local or metastatic invasion.^[27] Another study^[27] report that approximately 20-25% of the patients present locally advanced tumor (stage III) at the time of diagnosis and up to 53% of them already present metastases at the time of diagnosis.

In addition, the present study showed that 15.1% of patients were diagnosed in stage III and 65.8% in stage IV. This leads us to think that perhaps the diagnosis of pancreatic tumors in this particular center is taking longer than in other medical centers previous studies were conducted, causing the tumors to be diagnosed at more advanced stages. This can occur for several reasons, some of them being: the search for late medical care by the patient, less access to high-tech diagnostic equipment and accuracy, or even delays in the referral of the universal health system from the beginning of the investigation of the symptoms until its diagnosis.

The investigation of the existence of distant metastases after the diagnosis of a neoplasm always consists in procedures of extreme importance, since its presence already places the patient automatically in stage IV of the TNM, which affects the conducts and treatments that can be offered to that patient. When we refer to pancreatic cancer, the main sites to be investigated, as they are the most prevalent to present metastases, are: liver, peritoneum and lungs.^[12,28] In this study, as well as what is presented by several studies, the main organs presenting with metastases were liver (62.3% of patients with metastasis), peritoneum (38.1%) and lungs (11.6%). The consistency of this pattern is due to the pathways of dissemination (lymphatic, hematogenic and transcytic), that are linked to anatomic sites, with few variations from individuals and with almost no interference due to external factors.

The survival rate of pancreatic cancer is still low and the prognosis of this disease is reserved. According to consulted data, the 5-year overall survival rate is between 5%^[3] to 6%.^[17] Regarding survival rates, before completion of 30 days after the diagnosis, 92% of the patients were estimated to be alive.^[17] In the present study, the survival rate over the same period was 45.50%. Such disagreement may be related to the fact that the hospital in which

the medical records were analyzed is of a high level of complexity and therefore receives more severe patients, with advanced staging. Concerning survival over 10 months, the results were 15.40%, whereas in other studies suggest 12.6% after 1 year.^[17] Despite these discrepancies, low survival rates are observed in either studies, specially one year after its diagnosis.

Treatment of pancreatic cancer varies according to its histological type, staging and general evaluation of the patient. It is usually subdivided into three groups. The first would be for patients with potentially resectable, localized cancer. The second group includes the unresectable patients and the third group, the metastatic patients. This way, several treatments can be performed.^[13]

Even so, surgical resection is the only treatment that offers a potential cure for pancreatic cancer.^[2] However, since most patients present advanced stages, only a small part of them are eligible for curative surgery.^[1] Pancreaticoduodenectomy is most often performed on tumors of the head of the pancreas or periampullar neoplasms.^[13]

Other treatment modalities include radiation therapy, chemotherapy and immunotherapy. Studies have shown that adjuvant chemotherapy combined with radiotherapy have demonstrated greater survival rates over isolated chemotherapy. Isolated radiotherapy is used as a treatment, most of the time, to alleviate symptoms and prolong the survival of patients whose tumors cannot be resected. Another modalities available for treatment of pancreatic cancer are hormone therapy or immunotherapy, but no significant tumor benefits have been demonstrated.^[13]

After the approach of first treatment for pancreatic cancer, our study showed that 43 patients, (9.7%), were in complete remission; 6 (1.3%) were in partial remission, 73 (16%) in stable disease, 71 (16.0%) in progressing disease, 1 (0.2%) in cancer support therapy, 168 (37.8%) died and 83 (18.7%) did not apply for the criteria. Generally, no data is available in this section regarding pancreatic neoplasms. There are some reports arranged according to this categorization, but they include all forms of cancer. Thus, these results could not match basis for comparison.

Pancreatic cancer is recognized as a neoplasm with a high mortality rate, which represents 4% of cancer deaths in Brazil, although it represents only 2% of diagnosed cancers.^[1] Of the sample analyzed, it was observed that only 8 (1.8%) were alive, which shows a mortality rate very equivalent to its incidence.^[14] The high lethality of this type of neoplasia probably results from its late diagnosis, since in general they present nonspecific symptoms or are asymptomatic in the early stages.^[13,14,15] The rate of deceased patients, 61.1% (272) is assumed to be higher, since a portion of this datum was ignored when medical records were analyzed. That is, of the 73 (16.4%) medical records from which this information could

not be collected, probably the vast majority died considering the high mortality of pancreatic cancer. [13,15]

CONCLUSIONS

Based on the data obtained, the epidemiological surveillance of pancreatic cancer in the north region of the State of Rio Grande do Sul demonstrated a higher prevalence of pancreatic cancer in caucasian men, especially older than 56-years-old. The most common primarily location of the tumors was the pancreatic head, and, the main sites of metastasis were the liver, peritoneum and lungs.

Prognosis regarding the sample was not favorable, since most patients were diagnosed with metastatic tumors (stage IV). Most of the patients underwent surgery, followed or not by other treatments, and a high lethality rate was later observed.

Therefore, the results obtained with the present study can conclude that pancreatic cancer, in the north region of Rio Grande do Sul has similar epidemiological features as those already observed in international literature, with the exception of ethnicity. Late diagnosis contributes to the aggressive behavior of this disease, and to low overall survival rates.

These findings suggest the need for further studies concerning pancreatic neoplasm, that may be relevant for future adoption of preventive and diagnostic measures and which could modify perspectives regarding prognosis of the disease.

ACKNOWLEDGMENTS

We would like to thank Dr. Luciano Luiz Alt and Dr. Paulo Roberto Reichert for their educational incentive, as well as the University of Passo Fundo and São Vicente de Paulo Hospital for providing data and means so this article could be written.

REFERENCES

1. Instituto Nacional de Câncer (INCA). Câncer de pâncreas [Internet]. Brasília (DF): INCA; 2018; [access in 2018 Nov 08]. Available from: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-pancreas>
2. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain S. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* [Internet]. 2018 Nov; [cited ANO mês Dia]; 24(43):4846-61. Available from: <https://www.wjgnet.com/1007-9327/full/v24/i43/4846.htm>
3. Soldan M. Pancreatic cancer screening. *Rev Col Bras Cir* [Internet]. 2017 Apr; [cited 2019 Mar 05]; 44(2):109-11. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912017000200109&lng=en&tlng=en
4. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. *J Surg Oncol* [Internet]. 2012 May; [cited 2019 Apr 22]; 107(1):1-7. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.23149>
5. Gatti R, Pereira MAA, Giannella Neto D. Síndrome de von Hippel-Lindau. *Arq Bras Endocrinol Metabol* [Internet]. 1999 Oct; [cited 2019 Mar 13]; 43(5):377-88. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27301999000500011&lng=pt&tlng=pt
6. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. *Adv Surg* [Internet]. 2010 Sep; [cited 2019 Mar 02]; 44(1):293-311. Available from: [https://www.advancesurgery.com/article/S0065-3411\(10\)00012-6/fulltext](https://www.advancesurgery.com/article/S0065-3411(10)00012-6/fulltext)
7. Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. *World J Gastroenterol* [Internet]. 2014 Aug; [cited 2019 Apr 27]; 20(32):11182-98. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145757/>
8. Permut-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. *Familial Cancer* [Internet]. 2009 Sep; [cited 2019 May 22]; 8(2):109-17. Available from: <https://link.springer.com/article/10.1007%2Fs10689-008-9214-8>
9. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. *CA: Cancer J Clin* [Internet]. 2013 Jul; [cited 2019 Mar 26]; 63(5):318-48. Available from: <https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21190>
10. Castillo CF, Jimenez RE. Epidemiology and nonfamilial risk factors for exocrine pancreatic cancer. *UpToDate*. Weblog [Internet]. 2016; [cited 2018 Sep 11]; 1-10. Available from: <https://www.uptodate.com/contents/epidemiology-and-nonfamilial-risk-factors-for-exocrine-pancreatic-cancer>
11. American Cancer Society (ACS). Pancreatic cancer risk factors [Internet]. New York: ACS; 2019; [access in 2019 Feb 11]; Available from: <https://www.cancer.org/cancer/pancreatic-cancer/causes-risks-prevention/risk-factors.html>
12. Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?. *Cancer Epidemiol Biomarkers Prev* [Internet]. 2009 Sep; [cited 2019 Mar 22]; 18(9):2397-405. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630792/pdf/456162.pdf>
13. Chabner BA. Manual de oncologia de Harrison. 2nd ed. Porto Alegre: McGraw-Hill Global Education Holdings; 2015.

14. Xiao AY, Tan MLY, Wu LM, Asrani VM, Windsor JA. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. *Lancet Gastroenterol Hepatol*. [Internet]. 2016 Sep; [cited 2019 May 02]; 1(1):45-55. Available from: [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(16\)30004-8/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30004-8/fulltext)
15. Goldman L, Schafer AI. *Cecil Medicina Interna*. 24ª ed. Rio de Janeiro: Elsevier; 2012.
16. Ministério da Saúde (BR). Doação de órgãos – Pâncreas [Internet]. Brasília (DF): Ministério da Saúde; 2019; [access in 2019 Dec 05]. Available from: <http://www.saude.gov.br/saude-de-a-z/doacao-de-orgaos/pancreas>
17. Espindola LMD, Mota A, Gomes EAP, Campos OAM, Schneider IJC. Sobrevida em dois anos de pacientes acometidos por câncer de pâncreas e os fatores associados. *Arq Catarin Med* [Internet]. 2013 Apr/Jun; [cited 2019 Mar 15]; 42(2):62-9. Available from: <http://www.acm.org.br/revista/pdf/artigos/1230.pdf>
18. Rawla PR, Sunkara TS, Gaduputic VG. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. *World J Oncol* [Internet]. 2019 Feb; [cited 2019 May 13]; 10(1):10-27. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396775/#R26>
19. Barbosa IR, Santos CA, Souza ELB. Pancreatic cancer in Brazil: mortality trends and projections until 2029. *Arq Gastroenterol* [Internet]. 2018 Jul/Sep; [cited 2019 May 14]; 55(3):230-6. Available from: <http://www.scielo.br/pdf/ag/v55n3/1678-4219-ag-55-03-230.pdf>
20. Ilic M, Ilic I. Epidemiology of pancreatic cancer. *World J Gastroenterol* [Internet]. 2016 Nov; [cited 2019 May 13]; 22(44):9694-705. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124974/>
21. Mahdavifar N, Mohammadian M, Ghoncheh M, Salehiniya H. Pancreatic cancer in the world: an epidemiological review. *World Cancer Res J* [Internet]. 2018; [cited 2019 May 14]; 5(4):e1162-72. Available from: <https://www.wcrj.net/wp-content/uploads/sites/5/2018/12/e1162-Pancreatic-cancer-in-the-world-an-epidemiological-review.pdf>
22. World Health Organization (WHO). International Agency for Research on Cancer (IARC). The Global Cancer Observatory (GCO) [Internet]. France: IARC; [access in 2019 May 13]. Available from: <http://gco.iarc.fr/>
23. Kamphues C, Bova R, Schricke D, Hippler-Benschmidt M, Klauschen F, Stenzinger A, et al. Post-operative complications deteriorate long-term outcome in pancreatic cancer patients. *Ann Surg Oncol* [Internet]. 2012; [cited 2019 Feb 07]; 19(3):856-63. Available from: <https://link.springer.com/article/10.1245%2Fs10434-011-2041-4>
24. Torre GL, Waure C, Specchia M, Nicolotti N, Capizzi S, Bilotta A, et al. Does quality of observational studies affect the results of a meta-analysis?. The case of cigarette smoking and pancreatic cancer. *Pancreas* [Internet]. 2009 Apr; [cited 2019 Feb 07]; 38(3):241-7. Available from: <https://insights.ovid.com/pubmed?pmid=19307925>
25. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. *JAMA* [Internet]. 2001 Jul; [cited May 2019]; 286(2):169-70. Available from: <https://jamanetwork.com/journals/jama/article-abstract/1031415>
26. Muscat JE, Stellman SD, Hoffmann D, Wynder EL. Smoking and pancreatic cancer in men and women. *Cancer Epidemiol Biomarkers Prev* [Internet]. 1997 Jan; [cited 2019 Mar 03]; 6(1):9-15. Available from: <http://cebpa.aacrjournals.org/content/6/1/15.long>
27. Shore S, Vimalachandran D, Raraty MGT, Ghaneh P. Cancer in the elderly: pancreatic cancer. *Surg Oncol* [Internet]. 2004 Dec; [cited 2019 Mar 08]; 13(4):201-10. Available from: <https://www.sciencedirect.com/science/article/pii/S0960740404000659>
28. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. *CA: Cancer J Clin* [Internet]. 2008 Dec; [cited 2019 Feb 22]; 50(4):241-68. Available from: <https://onlinelibrary.wiley.com/doi/full/10.3322/canjclin.50.4.241?sid=nlm%3Apubmed>
29. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. *World J Gastroenterol* [Internet]. 2018 May; [cited 2019 Mar 14]; 24(19):2047-60. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960811/>
30. Rohde L, Osvaldt AB. *Rotinas em cirurgia digestiva*. 3rd ed. Porto Alegre: Artmed; 2018.
31. Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. *Cancer J* [Internet]. 2017 Oct; [cited 2019 Mar 18]; 23(6):333-42. Available from: <https://europepmc.org/abstract/med/29189329>
32. Scarà S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. In: Scatena R, ed. *Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology*. Dordrecht: Springer [Internet]. 2015; [cited 2019 May 03]; 867(1):247-60. Available from: https://link.springer.com/chapter/10.1007%2F978-94-017-7215-0_15
33. Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, et al. Pancreatic cancer epidemiology, detection, and management. *Gastroenterol Res Pract* [Internet]. 2016 Jan; [cited 2019 Mar 22]; 2016;(1):8962321. Available from: <https://www.hindawi.com/journals/grp/2016/8962321/>